PTGS2 and atopic conjunctivitis: The topical administration of TNF-α-activated MSCs to mice with experimental allergic conjunctivitis demonstrated a significant reduction in IL-4 and TNF-α levels and a drop in the number of inflammatory immune cells as well as NF-κB p65 expression via cyclooxygenase-2 (COX-2)-dependent mechanisms, which significantly improved the clinical outcome.